Current Strain of COVID: Omicron BA.5 Symptoms and Long COVID Concerns

Current Strain of COVID: Omicron BA.5 Symptoms and Long COVID Concerns
Table Of Content
Close

Understanding COVID-19 Variants and Strains

As the COVID-19 pandemic continues to evolve, tracking emerging variants and understanding their symptoms remains critical. Dominant strains like Omicron and its subvariants have distinct symptom profiles health authorities closely monitor to assess infection trends.

Defining COVID Variants and Strains

COVID variants refer to versions of the SARS-CoV-2 virus that carry distinct mutations. These mutations occur as the virus replicates and spreads through populations. Some mutations significantly alter properties like infectiousness, severity, and immune evasion.

A COVID strain describes a variant that has become widespread or dominant during a period of transmission. As new strains displace previously dominant ones, their characteristic mutations and symptoms may also shift over time.

Tracking Symptoms of Current Strains

Keeping current with the most widespread COVID strains and their common symptoms empowers individuals and public health measures. However, with new variants emerging, the predominant strains and associated symptoms continue to evolve.

Omicron: The Current Dominant Strain

Classified as a variant of concern by the WHO, Omicron remains the dominant COVID strain worldwide. Originally detected in late 2021, Omicron and its subvariants have rapidly spread due to exceptionally high transmissibility and immune evasion capabilities.

BA.5: Most Prevalent Omicron Subvariant

Among Omicron descendants, the BA.5 subvariant currently constitutes over 65% of sequenced cases globally. With enhanced growth advantages over other Omicron strains, BA.5 continues fueling infection resurgences more than 10 months into 2023.

Symptoms of Omicron BA.5

Many sources suggest Omicron infections cause less severe outcomes for most. However, research indicates BA.5 poses specific concerns:

  • Extreme infectiousness resulting in case spikes
  • Increased reinfection risk among those with previous Omicron cases
  • Higher severity relative to ancestral Omicron

Typical symptoms include:

  • Runny or stuffy nose
  • Headache
  • Fatigue
  • Sneezing
  • Sore throat
  • Fever
  • Persistent cough

Gastrointestinal issues sometimes also occur. Most symptoms resemble those of a heavy cold. Loss of smell and taste is less common compared to prior dominant strains.

Long COVID Concerns

In addition to acute infection symptoms, Long COVID poses lingering complications for a subset of cases. Characterized by debilitating effects persisting months post-recovery, estimates suggest 10-30% of infections lead to enduring symptoms.

Prevalence Following Omicron Infection

Growing research indicates Omicron variants may also contribute to Long COVID development. However, rates appear reduced relative to past strains like Delta:

  • UK study found 4.5% of Omicron cases lead to symptoms >12 weeks
  • Versus 10.8% after Delta infection

While lower percentages, Omicrons ultra transmissibility means substantial long-term disability across populations.

Common Long COVID Symptoms

Post-viral complications involve diverse effects spanning many bodily systems. Frequently reported symptoms include:

  • Extreme fatigue
  • Brain fog
  • Headaches
  • Dyspnea
  • Cough
  • Anxiety/depression
  • Muscle pain
  • Sleep disruption
  • Heart palpitations

These Oceans Seven Long COVID symptoms cause disability limiting work, social activities, and quality of life.

Vaccination Remains Vital

While infections continue propagating with new Omicron offshoots, health organizations emphasize vaccination remains vital to curtailing spread and severe outcomes.

Updated Boosters Target Omicron

As Omicron outpaced vaccine development, protection waned significantly over 2022. To counteract immune erosion and Long COVID risks, updated boosters released Fall 2022 better target BA.5 specifically:

  • Moderna bivalent booster
  • Pfizer bivalent booster

By eliciting Omicron-specific antibodies, boosted immunity defends against current strains to minimize acute sickness and enduring complications.

Booster Timing Recommendations

Guidance advises the following groups receive the new bivalent booster if at least 2 months passed since their last shot:

  • Age > 12 years
  • Completed initial vaccination series
  • Prior booster dose > 2 months ago

Staying up to date with available boosters offers optimal protection aligned with circulating variants.

The Path Ahead

Despite population fatigue, COVID-19 continues evolving with unpredictable turns. Maintaining surveillance of emerging strains and adhering to public health advice offers the best prospects for navigating whatever comes next.

As Omicron subvariants dominate entering 2023, tracking their characteristic symptoms and long-term effects remains essential. Meanwhile, leveraging updated vaccines and treatments promises a safer coexistence moving forward.

FAQs

What is the current dominant strain of COVID-19?

The Omicron BA.5 subvariant is presently the globally predominant strain, accounting for over 65% of new sequenced cases. Its enhanced transmissibility continues driving infection spikes.

What are the most common symptoms of Omicron BA.5?

Typical BA.5 symptoms resemble a severe cold, including runny nose, headache, fatigue, sore throat, fever, cough, and sometimes gastrointestinal distress. Loss of taste and smell is less common.

What percentage of Omicron cases lead to Long COVID?

Although estimates vary, studies suggest 4.5-10% of Omicron infections result in lingering Long COVID effects. Key symptoms involve fatigue, brain fog, headaches, breathing issues, anxiety, muscle pains, cough, sleep disruption and heart palpitations.

Who needs the new bivalent booster shots?

CDC recommends the Omicron-targeting bivalent booster for those over 12 years old who finished their primary vaccine series, with at least 2 months passing since their last dose for optimal protection.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a healthcare professional before starting any new treatment regimen.

Add Comment

Click here to post a comment

Related Coverage

The Latest on the Emerging BA.2.86 COVID Variant

Public health authorities are closely tracking the spread of BA.2.86, an Omicron subvariant with concerning mutations. Learn about detection, illness severity, vaccine efficacy, and expert predictions....

Paxlovid & Long COVID: What We Know

Paxlovid is transforming COVID treatment in 2025. Learn how this FDA-approved antiviral drug helps manage evolving symptoms, reduce hospitalization risks, and fight Long COVID....

Latest news